Page 3 - Afmd News Today

Affimed (NASDAQ:AFMD – Get Free Report)‘s stock had its “overweight” rating restated by equities researchers at Cantor Fitzgerald in a research note issued on Thursday, Benzinga reports. They currently have a $7.00 price target on the biopharmaceutical company’s stock. AFMD has been the subject of several other reports. HC Wainwright reaffirmed a “buy” rating and […]

Affimed (NASDAQ:AFMD – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year target price among analysts […]

Affimed (NASDAQ:AFMD – Free Report) had its target price trimmed by Truist Financial from $8.00 to $6.00 in a report released on Friday morning, Marketbeat reports. They currently have a buy rating on the biopharmaceutical company’s stock. AFMD has been the topic of a number of other research reports. Berenberg Bank restated a buy rating […]

Affimed (NASDAQ:AFMD – Free Report) – Research analysts at Cantor Fitzgerald issued their FY2024 EPS estimates for Affimed in a note issued to investors on Tuesday, July 11th. Cantor Fitzgerald analyst L. Watsek forecasts that the biopharmaceutical company will post earnings of ($0.37) per share for the year. The consensus estimate for Affimed’s current full-year […]

Affimed (NASDAQ:AFMD – Get Rating)’s stock price crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.97 and traded as low as $0.65. Affimed shares last traded at $0.65, with a volume of 15,772,533 shares traded. Analyst Ratings Changes A number […]

Investors have begun to flirt with a sector that has been distinctly out of favor for more than two years.

Boone Capital Management LLC bought a new position in shares of Affimed (NASDAQ:AFMD – Get Rating) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,869,744 shares of the biopharmaceutical company’s stock, valued at approximately $3,558,000. Affimed makes up about 1.8% of […]

Affimed (NASDAQ:AFMD – Get Rating) had its price objective trimmed by HC Wainwright from $6.00 to $5.00 in a research note published on Monday morning, The Fly reports. A number of other brokerages have also issued reports on AFMD. StockNews.com began coverage on shares of Affimed in a research note on Thursday, May 18th. They […]

Affimed (NASDAQ:AFMD – Get Rating) – Equities researchers at HC Wainwright increased their Q2 2023 earnings estimates for Affimed in a research report issued on Wednesday, May 24th. HC Wainwright analyst S. Ramakanth now expects that the biopharmaceutical company will earn ($0.23) per share for the quarter, up from their previous estimate of ($0.25). HC […]

Affimed (NASDAQ:AFMD – Get Rating) has been given an average recommendation of “Moderate Buy” by the eight brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average […]